Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Phase III Trial Finds Pfizer's Axitinib Better than Sorafenib at Boosting PFS ... - Genetic Engineering News |
 |
 |
|
Genetic Engineering News Pfizer reported positive data from a Phase III study comparing its VEGF receptor inhibitor axitinib with sorafenib therapy, in patients with advanced renal cell carcinoma whose disease had progressed after prior therapy with sunitinib (Pfizer's |
